DPC-082 is a reverse transcriptase inhibitor potentially for the treatment of HIV infection. DPC-082 exhibits low-nanomolar potency toward wild-type virus, K103N and L100I single-mutation variants, and multiplies amino acid-substituted HIV type 1 mutants. References: Corbett JW, Ko SS, Rodgers JD, Gearhart LA, Magnus NA, Bacheler LT, Diamond S, Jeffrey S, Klabe RM, Cordova BC, Garber S, Logue K, Trainor GL, Anderson PS, Erickson-Viitanen SK. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem. 2000 May 18;43(10):2019-30. PubMed PMID: 10821714.

纯度：≥98%

CAS：214287-98-6